知镜 Cognispect · 医学文献与研究工作台

Hematopoietic stem cell mobilization in relapsed or refractory lymphomas: A multi-center experience with BEGEV± rituximab.

Basci S, Erkurt MA, Sincan G, İskender D, Dagdas S, Ekinci O, Erer K, Demircan V, Batgi H, Kaya E, Erdem F, Guner SI, Kuku I, Yilmaz S, Yigenoglu TN, Korkmaz S, Altuntas F.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2026-11-13 · PMID 43033585

文献摘要

Background BEGEV (bendamustine, gemcitabine, vinorelbine, and prednisolone) is an established salvage regimen for relapsed/refractory Hodgkin lymphoma (HL), and previous studies have reported favorable stem cell mobilization outcomes. Most of these data, however, come from classical HL, while detailed experience in non-Hodgkin lymphoma (NHL) and mixed lymphoma cohorts remains limited. Methods We retrospectively evaluated 31 adults with HL or NHL who underwent BEGEV-based peripheral blood stem cell mobilization at multiple centers. The analysis included mobilization kinetics, peripheral blood and collected CD34 + cell counts, number of apheresis procedures, plerixafor use, hematologic toxicity, subsequent autologous stem cell transplantation (ASCT), and post-transplant engraftment. Successful mobilization was defined as collection of at least 2 × 10 6 CD34 + cells/kg. Results Of the 31 patients, 20 (64.5%) had HL and 11 (35.5%) had NHL. Thirteen (41.9%) had thrombocytopenia before mobilization, and four (12.9%) had previously failed mobilization. The median peripheral blood CD34 + cell concentration was 27 cells/µL, and the median total CD34 + cell yield was 4.3 × 10 6 /kg. A median of one apheresis procedure was required. Plerixafor was used in 12 patients (38.7%), and all 31 patients achieved successful collection. Febrile neutropenia occurred in seven patients (22.6%); red blood cell and platelet transfusions were required in 22.6% and 35.5%, respectively. Thirty patients (96.8%) proceeded to ASCT. Median neutrophil and platelet engraftment occurred on days 12 and 14, respectively. Conclusions BEGEV-based chemomobilization, with selective use of plerixafor, resulted in successful stem cell collection in all patients with HL or NHL, including those with a history of mobilization failure. Hematologic toxicity and supportive care requirements were not negligible, but almost all patients subsequently underwent ASCT and engraftment was satisfactory.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。